BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

XENE upcoming catalysts

Xenon Pharmaceuticals Inc.: 1 upcoming industry Phase 2/3 trial readout(s) in the next 90 days (1 Phase 3), 0 upcoming FDA decision event(s), and in the last 12 months 2 readout(s) and 0 FDA event(s). Subscribe to XENE (.ics).

Drugs: Azetukalner

Upcoming FDA decision events

DateEventStatusCompanyDrugSource
No upcoming PDUFA date or AdCom found.

Upcoming trial readouts

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2027-01 est.P3Xenon Pharmaceuticals Inc. XENENCT06922110 An Open-Label Study of Azetukalner in Major Depressive DisorderMajor Depressive Disorderactive not recruiting460

FDA decision events, last 12 months

DateEventStatusCompanyDrugSource
No FDA decision events in this window.

Trial readouts, last 12 months

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-10-28P3Xenon Pharmaceuticals Inc. XENENCT06775379 A Randomized Study of Azetukalner Versus Placebo in Major Depressive DisorderMajor Depressive Disorderterminated357
2026-01-12P3Xenon Pharmaceuticals Inc. XENENCT05614063 A Randomized Study of XEN1101 Versus Placebo in Focal-Onset SeizuresFocal Onset Seizurescompleted380

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.